Technical Analysis for CADL - Candel Therapeutics, Inc.

Grade Last Price % Change Price Change
B 9.93 -0.70% -0.07
CADL closed down 0.7 percent on Friday, September 24, 2021, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up
Historical CADL trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Shooting Star Candlestick Bearish -0.70%
New Uptrend Bullish -0.70%
Wide Bands Range Expansion -0.70%
Oversold Stochastic Weakness -0.70%
Crossed Above 20 DMA Bullish -0.90%
Older End-of-Day Signals for CADL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 15 hours ago
Down 1% about 15 hours ago
Possible NR7 about 15 hours ago
Possible Inside Day about 15 hours ago
Up 3% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Candel Therapeutics, Inc. Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Drugs Immunotherapy Surgery Cancer Immunotherapy Tumor Chemotherapy Radiation Pancreatic Cancer Metastases

Is CADL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.78
52 Week Low 5.51
Average Volume 159,097
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 8.87
10-Day Moving Average 8.66
Average True Range 1.27
ADX 26.25
+DI 31.80
-DI 14.82
Chandelier Exit (Long, 3 ATRs) 10.98
Chandelier Exit (Short, 3 ATRs) 10.90
Upper Bollinger Bands 11.26
Lower Bollinger Band 6.47
Percent B (%b) 0.72
BandWidth 54.02
MACD Line 0.41
MACD Signal Line 0.34
MACD Histogram 0.0689
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.67
Resistance 3 (R3) 10.72 10.54 10.54
Resistance 2 (R2) 10.54 10.35 10.51 10.50
Resistance 1 (R1) 10.23 10.23 10.14 10.18 10.46
Pivot Point 10.05 10.05 10.00 10.02 10.05
Support 1 (S1) 9.74 9.86 9.65 9.69 9.40
Support 2 (S2) 9.56 9.74 9.53 9.36
Support 3 (S3) 9.25 9.56 9.32
Support 4 (S4) 9.20